Immunohistochemical analysis revealed down regulation of the expression of VEGFR-2, PDGFR-β, and c-Kit suggesting that targeting of class III/V receptor tyrosine kinases and their ligands can suppress neuroblastoma tumorigenicity and angiogenesis [23]. Here, PDGFRB is linked to neuroblastoma.